Grünenthal today announced the acquisition of US-based Valinor Pharma, LLC (“Valinor”) and its product Movantik® (naloxegol), with a total deal value of approx. 0 million...
• Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. • Grünenthal is running a gl...
A virtual marketplace leading your business into the future
